Impact of prior melphalan exposure on stem cell collection in light chain amyloidosis

Surbhi Sidana, Nidhi Tandon, Morie Gertz, Angela Dispenzieri, Francis K. Buadi, Martha Lacy, David M Dingli, Amie L. Fonder, Suzanne R. Hayman, Miriam A. Hobbs, Wilson Gonsalves, Yi Lisa Hwa, Prashant Kapoor, Robert A. Kyle, Nelson Leung, Ronald S. Go, John A. Lust, Stephen J Russell, Steven R. Zeldenrust, S Vincent Rajkumar & 2 others William Hogan, Shaji K Kumar

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Use of melphalan in multiple myeloma was observed to have a deleterious effect on stem cell collection in older studies. There is limited data on the impact of melphalan in light chain (AL) amyloidosis, especially in the plerixafor era. We retrospectively evaluated stem cell mobilization in 610 patients with AL amyloidosis, of which 79 had prior exposure to melphalan, 167 to other chemotherapeutics, while 364 had no chemotherapy exposure. Collection of CD34+ stem cells × 106/kg was lower in the melphalan group. Median total yields in the melphalan, non-melphalan, and no chemotherapy groups were 5.5, 7.7, and 7.8, respectively; p < 0.001. Day-1 yields were 2.7, 3.5, and 4.0 (p = 0.0003), respectively, and median yields per collection were 2.0, 3.3, and 4.0 (p < 0.001), respectively. Similar results were observed in the sub-group analysis after plerixafor was integrated in our collection algorithm (2009). Patients in the melphalan group had higher failure rate of 9% vs. 2% each in the other two groups (p = 0.006). Impact of melphalan was dose-dependent, with cumulative melphalan exposure of >150 mg (median: three cycles) resulting in lower yields. Therefore, duration of melphalan exposure prior to stem cell collection should be limited, ideally, not exceeding more than two cycles of treatment.

Original languageEnglish (US)
Pages (from-to)1-8
Number of pages8
JournalBone Marrow Transplantation
DOIs
StateAccepted/In press - Dec 21 2017

Fingerprint

Melphalan
Amyloidosis
Stem Cells
Light
Hematopoietic Stem Cell Mobilization
Drug Therapy
Multiple Myeloma

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Impact of prior melphalan exposure on stem cell collection in light chain amyloidosis. / Sidana, Surbhi; Tandon, Nidhi; Gertz, Morie; Dispenzieri, Angela; Buadi, Francis K.; Lacy, Martha; Dingli, David M; Fonder, Amie L.; Hayman, Suzanne R.; Hobbs, Miriam A.; Gonsalves, Wilson; Hwa, Yi Lisa; Kapoor, Prashant; Kyle, Robert A.; Leung, Nelson; Go, Ronald S.; Lust, John A.; Russell, Stephen J; Zeldenrust, Steven R.; Rajkumar, S Vincent; Hogan, William; Kumar, Shaji K.

In: Bone Marrow Transplantation, 21.12.2017, p. 1-8.

Research output: Contribution to journalArticle

Sidana, Surbhi ; Tandon, Nidhi ; Gertz, Morie ; Dispenzieri, Angela ; Buadi, Francis K. ; Lacy, Martha ; Dingli, David M ; Fonder, Amie L. ; Hayman, Suzanne R. ; Hobbs, Miriam A. ; Gonsalves, Wilson ; Hwa, Yi Lisa ; Kapoor, Prashant ; Kyle, Robert A. ; Leung, Nelson ; Go, Ronald S. ; Lust, John A. ; Russell, Stephen J ; Zeldenrust, Steven R. ; Rajkumar, S Vincent ; Hogan, William ; Kumar, Shaji K. / Impact of prior melphalan exposure on stem cell collection in light chain amyloidosis. In: Bone Marrow Transplantation. 2017 ; pp. 1-8.
@article{7485b8b550de4a8bb2a77720fb0aea96,
title = "Impact of prior melphalan exposure on stem cell collection in light chain amyloidosis",
abstract = "Use of melphalan in multiple myeloma was observed to have a deleterious effect on stem cell collection in older studies. There is limited data on the impact of melphalan in light chain (AL) amyloidosis, especially in the plerixafor era. We retrospectively evaluated stem cell mobilization in 610 patients with AL amyloidosis, of which 79 had prior exposure to melphalan, 167 to other chemotherapeutics, while 364 had no chemotherapy exposure. Collection of CD34+ stem cells × 106/kg was lower in the melphalan group. Median total yields in the melphalan, non-melphalan, and no chemotherapy groups were 5.5, 7.7, and 7.8, respectively; p < 0.001. Day-1 yields were 2.7, 3.5, and 4.0 (p = 0.0003), respectively, and median yields per collection were 2.0, 3.3, and 4.0 (p < 0.001), respectively. Similar results were observed in the sub-group analysis after plerixafor was integrated in our collection algorithm (2009). Patients in the melphalan group had higher failure rate of 9{\%} vs. 2{\%} each in the other two groups (p = 0.006). Impact of melphalan was dose-dependent, with cumulative melphalan exposure of >150 mg (median: three cycles) resulting in lower yields. Therefore, duration of melphalan exposure prior to stem cell collection should be limited, ideally, not exceeding more than two cycles of treatment.",
author = "Surbhi Sidana and Nidhi Tandon and Morie Gertz and Angela Dispenzieri and Buadi, {Francis K.} and Martha Lacy and Dingli, {David M} and Fonder, {Amie L.} and Hayman, {Suzanne R.} and Hobbs, {Miriam A.} and Wilson Gonsalves and Hwa, {Yi Lisa} and Prashant Kapoor and Kyle, {Robert A.} and Nelson Leung and Go, {Ronald S.} and Lust, {John A.} and Russell, {Stephen J} and Zeldenrust, {Steven R.} and Rajkumar, {S Vincent} and William Hogan and Kumar, {Shaji K}",
year = "2017",
month = "12",
day = "21",
doi = "10.1038/s41409-017-0020-5",
language = "English (US)",
pages = "1--8",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Impact of prior melphalan exposure on stem cell collection in light chain amyloidosis

AU - Sidana, Surbhi

AU - Tandon, Nidhi

AU - Gertz, Morie

AU - Dispenzieri, Angela

AU - Buadi, Francis K.

AU - Lacy, Martha

AU - Dingli, David M

AU - Fonder, Amie L.

AU - Hayman, Suzanne R.

AU - Hobbs, Miriam A.

AU - Gonsalves, Wilson

AU - Hwa, Yi Lisa

AU - Kapoor, Prashant

AU - Kyle, Robert A.

AU - Leung, Nelson

AU - Go, Ronald S.

AU - Lust, John A.

AU - Russell, Stephen J

AU - Zeldenrust, Steven R.

AU - Rajkumar, S Vincent

AU - Hogan, William

AU - Kumar, Shaji K

PY - 2017/12/21

Y1 - 2017/12/21

N2 - Use of melphalan in multiple myeloma was observed to have a deleterious effect on stem cell collection in older studies. There is limited data on the impact of melphalan in light chain (AL) amyloidosis, especially in the plerixafor era. We retrospectively evaluated stem cell mobilization in 610 patients with AL amyloidosis, of which 79 had prior exposure to melphalan, 167 to other chemotherapeutics, while 364 had no chemotherapy exposure. Collection of CD34+ stem cells × 106/kg was lower in the melphalan group. Median total yields in the melphalan, non-melphalan, and no chemotherapy groups were 5.5, 7.7, and 7.8, respectively; p < 0.001. Day-1 yields were 2.7, 3.5, and 4.0 (p = 0.0003), respectively, and median yields per collection were 2.0, 3.3, and 4.0 (p < 0.001), respectively. Similar results were observed in the sub-group analysis after plerixafor was integrated in our collection algorithm (2009). Patients in the melphalan group had higher failure rate of 9% vs. 2% each in the other two groups (p = 0.006). Impact of melphalan was dose-dependent, with cumulative melphalan exposure of >150 mg (median: three cycles) resulting in lower yields. Therefore, duration of melphalan exposure prior to stem cell collection should be limited, ideally, not exceeding more than two cycles of treatment.

AB - Use of melphalan in multiple myeloma was observed to have a deleterious effect on stem cell collection in older studies. There is limited data on the impact of melphalan in light chain (AL) amyloidosis, especially in the plerixafor era. We retrospectively evaluated stem cell mobilization in 610 patients with AL amyloidosis, of which 79 had prior exposure to melphalan, 167 to other chemotherapeutics, while 364 had no chemotherapy exposure. Collection of CD34+ stem cells × 106/kg was lower in the melphalan group. Median total yields in the melphalan, non-melphalan, and no chemotherapy groups were 5.5, 7.7, and 7.8, respectively; p < 0.001. Day-1 yields were 2.7, 3.5, and 4.0 (p = 0.0003), respectively, and median yields per collection were 2.0, 3.3, and 4.0 (p < 0.001), respectively. Similar results were observed in the sub-group analysis after plerixafor was integrated in our collection algorithm (2009). Patients in the melphalan group had higher failure rate of 9% vs. 2% each in the other two groups (p = 0.006). Impact of melphalan was dose-dependent, with cumulative melphalan exposure of >150 mg (median: three cycles) resulting in lower yields. Therefore, duration of melphalan exposure prior to stem cell collection should be limited, ideally, not exceeding more than two cycles of treatment.

UR - http://www.scopus.com/inward/record.url?scp=85038610080&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038610080&partnerID=8YFLogxK

U2 - 10.1038/s41409-017-0020-5

DO - 10.1038/s41409-017-0020-5

M3 - Article

SP - 1

EP - 8

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

ER -